title: [Therapeutic plasmapheresis in systemic lupus erythematosus].
abstract: Nine patients with SLE were treated with plasmapheresis (PP); eight of them having active disease improved rapidly and significantly both in clinical and laboratory parameters. The longest remission period was up to 17 months. The common side effects were hypocalcemia and urticaria but they did not necessitate cessation of therapy. The following treatment course is suggested: PP two to three times a week for two weeks with an exchange amount of 1.5 liters of plasma each time. In order to prevent the patients from antibody rebound phenomenon, administration of steroids and immunosuppressive agents following PP treatment is necessary.
authors.affiliation: China-Japan Friendship Hospital.
authors.forename: H L
authors.initials: HL
authors.lastname: Cui
authors.forename: L
authors.initials: L
authors.lastname: Ma
authors.forename: R Q
authors.initials: RQ
authors.lastname: Zhu
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D008297:Male; D010956:Plasmapheresis / Q000009:adverse effects / Q000379:methods; D011241:Prednisone / Q000627:therapeutic use; D014581:Urticaria / Q000209:etiology
chemical_list: D003520:Cyclophosphamide; D011241:Prednisone